Literature DB >> 18698050

Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease.

Mariano Provencio1, Isabel Millán, Pilar España, Antonio C Sánchez, José J Sánchez, Blanca Cantos, Juan A Vargas, Carmen Bellas, Vanesa García, Pilar Sabin, Félix Bonilla.   

Abstract

PURPOSE: Hodgkin's disease is considered a model of curable illness. However, long-term studies show excessive mortality in relation to the general population. We studied the various causes of death by use of competing risks and their evolution over the years. EXPERIMENTAL
DESIGN: All patients diagnosed with Hodgkin's disease at our institution between 1967 and 2003 were included. The competing risks of causes of death and their vital situation were examined in three time periods: cohort A with patients treated before 1980, cohort B with patients treated from 1981 to 1986, and cohort C with patients treated from 1986 onwards.
RESULTS: We studied 534 patients, with a median follow-up time of 9.1 years for the whole cohort. The 5-year, 15-year, and 20-year Kaplan-Meier survival estimates for all patients were 81%, 72%, and 65%, respectively. At the close of the study, 337 (63.1%) were alive and 170 (31.8%) patients had died. The most common cause of death was the progression of Hodgkin's disease, followed by deaths due to a second tumor. Survival was significantly worse in the first period than in the other two (P < 0.001), and in the three periods, the main cause of death was tumor progression.
CONCLUSIONS: The progression of Hodgkin's disease is the main cause of death. Over time, a reduction in death related to infection and the acute toxicity of treatment was seen. A lot of patients still die for reasons linked to delayed side effects of radiotherapy, such as second tumors and heart disease, which is important to plan preventive activities and clinical research.

Entities:  

Mesh:

Year:  2008        PMID: 18698050     DOI: 10.1158/1078-0432.CCR-07-0927

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain.

Authors:  J L Cruz-Bermúdez; C Parejo; F Martínez-Ruíz; J C Sánchez-González; A Ramos Martín-Vegue; A Royuela; A Rodríguez-González; E Menasalvas-Ruiz; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-03-12       Impact factor: 3.405

2.  Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.

Authors:  E Almagro-Casado; A Sánchez; B Cantos; C Salas; D Pérez-Callejo; M Provencio
Journal:  Clin Transl Oncol       Date:  2015-11-03       Impact factor: 3.405

3.  Incidence patterns and outcomes for hodgkin lymphoma patients in the United States.

Authors:  Pareen Shenoy; Alison Maggioncalda; Neha Malik; Christopher R Flowers
Journal:  Adv Hematol       Date:  2010-12-16

4.  Early Competing Deaths in Locally Advanced Head-and-Neck Cancer.

Authors:  Sandeep Muzumder; S Nirmala; H U Avinash; Prashanth Bhat Kainthaje; Mg John Sebastian; John Michael Raj
Journal:  Indian J Palliat Care       Date:  2018 Oct-Dec

5.  Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.

Authors:  E M Bessell; G Bouliotis; S Armstrong; J Baddeley; A P Haynes; S O'Connor; H Nicholls-Elliott; M Bradley
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.